一、EGFR在非小细胞肺癌驱动基因中占比最高，是非小细胞肺癌治疗主要靶点之一 肺癌是仅次于乳腺癌的第二大常见癌症，其中非小细胞肺癌是最常见的肺癌类型。2020 年，全球肺癌占全部癌症种类的 11.1%，其中非小细胞肺癌发病数量约占肺癌总数的 85%左右。

在肺癌治疗中，EGFR 酪氨酸激酶抑制剂（EGFR-TKIs）耐药问题突出。研究人员聚焦肺腺癌，探究癌胚抗原细胞黏附分子 6（CEACAM6）与 EGFR 信号及耐药关系。结果发现 CEACAM6 影响 EGFR 稳定性和 TKI 敏感性。这为肺癌治疗提供新方向。 肺癌，作为全球范围内严重威胁 ...

在癌症研究中，EGFR 突变与多种恶性肿瘤相关，其激活 mTORC1的机制尚未完全明晰。研究人员开展了 EGFR 对 mTORC1激活作用的研究，发现溶酶体定位的 EGFR 可作为 Rheb 的 GEF 激活 mTORC1，为癌症治疗提供新策略。 在生命的微观世界里，细胞的生长和代谢如同精密的 ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of amivantamab plus lazertinib in patients with EGFR-mutated non–small cell lung cancer.

The c-Met protein thought to be both a driver of cancer itself, as well as a resistance mechanism that tumours can develop to protect them from some widely-used NSCLC therapies, including EGFR ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

On Saturday at 2:59 a.m., the Alpena Township Fire Department was dispatched for a commercial structure fire at 2568 U.S.-23 South, according to a Monday press release. Upon arrival, crews found ...

肺癌，这一恶性肿瘤，在我国的发病率及死亡率均高居榜首，堪称头号癌症“杀手”。非小细胞肺癌（NSCLC）作为最常见的肺癌类型，其五年生存率仅为20%，而对于那些携带EGFR 20号外显子插入突变（EGFR Exon20ins）的患者而言，这一数字更是低至不足10%。其中 ...

The corps is a holistic structure. And let’s not even talk about the ‘attached’ units that break brigades into battalions and, let’s be honest, are not valued as much as the ‘main’ ones. It is time to ...